Document Type : Original Research
Dept. of Internal Medicine, Semnan University of Medical Science, Semnan, Iran
Dept. of Pathology, Semnan University of Medical Science, Semnan, Iran
Dept. of Pathology, Shahid Beheshti University of Medical Science, Tehran, Iran
Background and Objectives: Cyclooxygenese-2 (COX-2) expression in breast cancer and its correlation with tumor prognosis is unclear. We investigated the incidence of COX-2 expression in patients and assessed interactions between COX-2 and clinical features of cancer and expression of HER2/neu, estrogen receptor (ER), and progesterone receptor (PR).
Methods: COX-2 expression was investigated by immunohistochemistry in 29 patients’ specimens diagnosed as primary breast cancer between 2006 and 2008 at the Fatemieh Hospital, Semnan, Iran. Relationship between COX-2 expression and age, histological grade, histological type, nodal status, and hormone receptor status were evaluated.
Results: We used IHC method although it was not a quantitative study. Its expression depends on quality of antibody, staining and selection of analyzed region. COX-2, HER-2, ER, and PR were detected in 89.7%, 51.7%, 82.8%, and 79.3% of samples, respectively. Elevated COX-2 expression was not associated with size and grade of tumor, while mean numbers of involved lymph nodes was significantly higher in those with elevated expression of COX-2 (P = 0.001). There were no significant correlations between COX-2 expression and HER-2, ER, and PR receptors.
Conclusion: Only tumor tissue was analyzed and did not compare to normal tissue. Elevated COX-2 expression can be found in most patients with breast cancer and has a crucial role in tumor differentiation regarding degree of lymph node involvement. It seems that correlation between COX-2 and other oncogens and hormonal receptors might be influenced by geographical and racial factors, so, assessment of these relationships in each patient's population may be necessary.
- Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta1996; 1299(1):125–40.
- Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res1996;56(19):4424–9.
- Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 1998;273(34):22120–.
- Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AMC. Transcriptional activation of cyclooxygenase-2 in Wnt-1–transformed mouse mammary epithelial cells. Cancer Res1999; 59:1572–7.
- Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene1999;18(2):305–14.
- Haertel-Wiesmann M, Liang Y, Fantl WJ, Williams LT. Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. J Biol Chem2000;275:32046–51.
- Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94(7):3336–40.
- Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, et al. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett 1999;460(1):145–8.
- Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003;7(3):207-22.
- Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K, et al . Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A2009; 106(9):3372-7.
- Miglietta A, Toselli M, Ravarino N, Vencia W, Chiecchio A, Bozzo F, et al. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers. Expert Opin Ther Targets 2010;14(7):655-64.
- Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C. COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 2007;15(3):255-9.
- Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 2011;130(2):657-62.
- Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P, Ghilchik M, et al. The mRNA expression of cyclooxygenase-2 and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 2002;18:237–41.
- Singh Ranger G, Mokbel K. COX-2 inhibitors and breast cancer. ANZ J Surg 2003;73(8):565-6.
- Takkouche B, Regueira-Méndez C, Etminan M .Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008;100(20):1439-47.
- Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor in a rat mammary tumor model. Oncol Rep 2000;7:1377–81.
- Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol 2009;15;78(10):1298-304.
- Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib . J Clin Oncol 2008;26(8):1253–9.
- Bonberg EM. Reduced Expression of Cyclooxygenase-2 in Primary Breast Cancer. J Natl Cancer Inst. 2008;100(14):1042-3.
- Bocca C, Bozzo F, Bassignana A, Miglietta A. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011;350(1-2):59-70.
- Nam E, Lee SN, Im SA, Kim DW, Lee KE, Sung SH. Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors. Cancer Res Treat 2005;37(3):165-70.
- Lucarelli AP, Martins MM, Montor W, Oliveira V, Galvão MAL, Piato S. Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.Sao Paulo Med J 2011;129(6):371-9.
- Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007;131(1):18-43.
- IHC scoring system according to the guidelines given by ASCO/CAP. Available in: http://www.nordiqc.org/Run-36-B14-H2/Assessment/assessment-B14-HER2.htm
- Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004; 31(1 Suppl 3):64-73.
- Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 2004;4(6):428-33.
- Ahn JH, Kim SB, Ahn SH, Gong GY, Ahn MJ, Kang YK, et al. Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma. Cancer Res Treat 2004;36(3): 192–8.
- Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004;31(2 Suppl 7):22-9.
- Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30(3):377-86.
- Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004; 45(1):47-54.